Product image of Lercamed (Lercanidipine Hydrochloride) supplied by GNH India

Lercamed

Active Ingredient:
Lercanidipine Hydrochloride
Origin:
EU

Lercamed (Lercanidipine Hydrochloride)

Lercanidipine, the active ingredient in Lercamed, is a dihydropyridine calcium channel blocker presented as an oral tablet for oral use. It is prescribed to lower elevated blood pressure in adults with hypertension and works by selectively relaxing vascular smooth muscle, improving arterial compliance and reducing systemic vascular resistance.

GNH India supplies Lercamed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled manufacturing and reliable distribution across global markets. The company adheres to stringent regulatory standards and provides comprehensive support for product registration and logistics.

Manufacturer / TM Owner

Omet Pharma Ab

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lercamed (lercanidipine) is used to manage high blood pressure by targeting the calcium‑channel pathway that controls vascular tone.

  • Essential hypertension: reduces both systolic and diastolic pressure in patients with primary hypertension.
  • Isolated systolic hypertension: helps control elevated systolic pressure, particularly in older adults.
  • Hypertensive patients with cardiovascular risk: contributes to overall blood pressure control as part of risk‑reduction strategies.

How It Works

  • Lercanidipine selectively blocks L‑type calcium channels in vascular smooth‑muscle cells, preventing calcium influx that is necessary for contraction. This inhibition leads to relaxation of arterial smooth muscle, causing vasodilation, decreased peripheral resistance, and ultimately a reduction in systemic blood pressure. The drug exhibits a high affinity for peripheral vessels while sparing cardiac conduction tissues, which contributes to its antihypertensive efficacy with a favorable cardiac safety profile.

Side Effects

Lercamed may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Headache
  • Flushing
  • Peripheral edema
  • Dizziness
  • Tachycardia
  • Fatigue

Serious or Rare Side Effects

  • Angioedema
  • Severe hypotension
  • Myocardial infarction
  • Hepatic injury
  • Atrioventricular block
  • Allergic rash

Precautions & Warnings

When prescribing Lercamed, clinicians should consider several precautionary measures to ensure safe use.

  • Monitor blood pressure: check regularly after therapy initiation and dose adjustments.
  • Assess renal function: evaluate kidney status before starting and during treatment.
  • Avoid abrupt discontinuation: taper the dose to prevent rebound hypertension.
  • Caution in elderly: increased sensitivity to hypotensive effects may occur.
  • Pregnancy and lactation: use only if the potential benefit outweighs the unknown risk.
  • Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Lercamed can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid)

  • CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations.
  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.
  • Concomitant use with other antihypertensives: risk of excessive hypotension.
  • Grapefruit juice: can elevate drug levels and precipitate adverse events.

Moderate Interactions (Monitor Closely)

  • Diuretics: monitor electrolytes and volume status.
  • Beta‑blockers: observe for additive bradycardia or hypotension.

Frequently Asked Questions

Lercamed contains lercanidipine, which is prescribed to treat hypertension. By lowering elevated systolic and diastolic blood pressure, it helps reduce the risk of cardiovascular complications associated with sustained high blood pressure.

Lercanidipine blocks L‑type calcium channels on vascular smooth‑muscle cells. This prevents calcium‑driven contraction, leading to relaxation of arterial walls, vasodilation, and a decrease in peripheral vascular resistance, which ultimately lowers systemic blood pressure.

The appropriate dose of Lercamed is determined by the prescribing clinician based on the individual’s blood‑pressure profile, age, renal function and concomitant therapies. Dosage adjustments are made according to therapeutic response and tolerability.

Safety data for lercanidipine in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Lercamed, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both lercanidipine and amlodipine belong to the dihydropyridine calcium‑channel blocker class and lower blood pressure by vasodilation. Lercanidipine has a longer half‑life and may provide smoother 24‑hour blood‑pressure control, while amlodipine is more widely used and has a longer market history.

Lercamed tablets should be stored at ambient temperature below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use after the expiry date.

Lercamed is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the prescribing physician’s instructions regarding timing and any required dose adjustments.

Serious adverse reactions, although rare, include angioedema, severe hypotension, myocardial infarction, hepatic injury and atrioventricular block. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, chest pain or signs of liver dysfunction.

Lercamed is contraindicated in patients with known hypersensitivity to lercanidipine or any other dihydropyridine calcium‑channel blocker. Caution is also advised for individuals with severe aortic stenosis, unstable angina, or those who are pregnant or breastfeeding unless clearly indicated by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lercanidipine Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT